Last close As at 05/08/2026
GBP2.22
▲ 1.00 (0.45%)
Market capitalisation
GBP508m
Research: TMT
GB Group (GBG) reported strong underlying revenue growth for FY22 while profitability growth reflected the resumption of investment in the business. GBG has demonstrated the ability to navigate challenges with its performance over the COVID-19 pandemic and we view its diversified business (by geography and vertical) as a strength in an uncertain market environment. Our forecasts are substantially unchanged and in our view the valuation has become increasingly detached from the company’s growth potential.
GB Group |
Capitalising on recent strategic investment |
FY22 results |
Software and comp services |
20 June 2022 |
Share price performance
Business description
Next events
Analyst
GB Group is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||
GB Group (GBG) reported strong underlying revenue growth for FY22 while profitability growth reflected the resumption of investment in the business. GBG has demonstrated the ability to navigate challenges with its performance over the COVID-19 pandemic and we view its diversified business (by geography and vertical) as a strength in an uncertain market environment. Our forecasts are substantially unchanged and in our view the valuation has become increasingly detached from the company’s growth potential.
Year end |
Revenue |
Adj. op. profit* (£m) |
PBT* |
Diluted EPS* |
DPS |
P/E |
03/21 |
217.7 |
57.9 |
56.7 |
22.4 |
6.4 |
19.7 |
03/22 |
242.5 |
58.8 |
57.1 |
20.2 |
3.8 |
21.9 |
03/23e |
300.8 |
72.2 |
67.7 |
20.4 |
4.0 |
21.6 |
03/24e |
337.0 |
81.7 |
78.0 |
22.8 |
4.3 |
19.4 |
03/25e |
379.5 |
92.3 |
89.4 |
25.9 |
4.6 |
17.0 |
Note: *Adjusted operating profit, PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
FY22 a return to more normal trading
After an exceptional year in FY21 when GBG benefited from a US stimulus contract, disposed of several businesses and reduced costs to manage through the COVID-19 pandemic, trading in FY22 reverted to more normal levels and the company resumed investing in the business, both organically and via the acquisitions of Acuant and Cloudcheck. Revenue grew 11.4% (10.6% constant currency organic, 15.5% on an underlying basis) and adjusted operating profit grew 1.6% y-o-y with a margin of 24.3%. The company paid down £30m of acquisition debt to close the year with net debt of £107m and gearing of 1.7x.
Focused on maximising opportunity from Acuant
After the strategic acquisition of Acuant in November 2021, GBG has a strengthened position in the US, the largest market for identity verification. With a large proportion of the integration complete, GBG is now focused on driving revenue synergies from the deal and using the technology acquired to accelerate the group’s product roadmap.
Valuation: Not capturing growth potential
The share price is down c 40% year-to-date and is trading on a P/E of 21.6x FY23e and 19.4x FY24e, the lowest level since autumn 2019, bar the dip in March 2020. As GBG trades through H123 and gains a better idea of underlying growth and the scale of revenue synergies from the Acuant deal, it should be able to provide the market with confidence that FY23 estimates are achievable and that the acquisition of Acuant is delivering on its promise. Our reverse discounted cash flow (DCF) implies the share price is discounting organic revenue growth of c 3% from FY26, well below the double-digit growth rate GBG has consistently achieved. Considering that Acuant is expected to grow faster than the core GBG business, this appears overly conservative. Using a 12% growth rate (the lower end of management guidance) from FY26 would imply a value per share of 749p.
Review of FY22 results
Exhibit 1: FY22 results versus forecasts and FY21
£m |
|
|
|
|
|
FY21a |
FY22e |
FY22a |
diff |
y-o-y |
|
Revenue |
217.7 |
242.0 |
242.5 |
0.2% |
11.4% |
Gross profit |
152.6 |
174 |
172 |
(1.3%) |
12.7% |
Gross margin |
70.1% |
72.0% |
70.9% |
(1.1%) |
0.8% |
EBITDA |
61.4 |
61.7 |
62.2 |
0.9% |
1.3% |
EBITDA margin |
28.2% |
25.5% |
25.6% |
0.2% |
(2.6%) |
EBIT |
57.9 |
58.0 |
58.8 |
1.5% |
1.6% |
EBIT margin |
26.6% |
24.0% |
24.3% |
0.3% |
(2.3%) |
PBT |
56.7 |
56.3 |
57.1 |
1.4% |
0.8% |
EPS - normalised, diluted (p) |
22.4 |
20.5 |
20.2 |
(1.5%) |
(9.9%) |
EPS - reported (p) |
13.8 |
9.9 |
7.1 |
(28.7%) |
(48.7%) |
DPS (p) |
6.40 |
3.50 |
3.81 |
8.9% |
(40.5%) |
Net debt/(cash) |
(21.1) |
107.4 |
105.9 |
(1.3%) |
(601.2%) |
Net debt/EBITDA |
N/A |
1.7 |
1.7 |
Source: GB Group, Edison Investment Research
GBG reported revenue growth of 11.4% for FY22. Excluding acquisitions and adjusting for currency, the group grew 10.6% on an organic basis. Also excluding the one-off benefit from the US stimulus programme in FY21, underlying growth was 15.5%. Pro forma revenue for FY22 was £273.8m, including £29.9m from acquisitions before the acquisition date and the £1.4m deferred revenue adjustment for Acuant.
Adjusted operating profit was 1.6% higher y-o-y, generating a margin of 24.3% compared to 26.6% in FY21. In FY21, revenues benefited from the US stimulus programme and the company cut travel and marketing spend during the pandemic, resulting in a one-off boost to profitability.
Exceptional items totalled £4.5m consisting of acquisition-related costs (£5.6m), gain on forward contracts linked to acquisitions (£3.1m), integration costs (£0.4m), reorganisation costs (£1.1m), FX movement on contingent consideration (£0.2m) and loss on disposal of businesses (£0.3m).
The tax rate on reported PBT was 29.5%, higher than 21.6% in FY21 mainly due to non-deductible costs related to acquisitions. The effective rate on normalised PBT was 22.1%, higher than our 20% forecast.
Normalised diluted EPS of 20.2p was marginally lower than our 20.5p forecast due to the combination of the higher effective tax rate and slightly higher dilutive share count (220.5m vs our 219.9m forecast).
The company declared a dividend of 3.81p for the year and reiterated its commitment to a progressive dividend. This was above our 3.5p forecast and 12% higher than last year’s final dividend.
Year-end net debt stood at £107.0m after taking account of £1m in unamortised loan fees (£105.9m on the balance sheet). The company repaid £30.1m of the £157m debt drawn down to finance the Acuant acquisition. Adjusted EBITDA was converted to cash at a rate of 95.7% compared to 119.5% in FY21, reflecting increased working capital requirements as the business grew.
Divisional performance
We note the company changed the way it allocates central costs during the year. In FY21, a proportion of central costs were allocated to each division. In FY22 it was decided that only those costs that could be controlled by a division would be allocated to it. This means a year-on-year comparison of margins is not meaningful.
■
Fraud: revenue grew 17.1% y-o-y on a reported basis and 15.7% on a constant currency organic basis, benefiting from the resumption of on-premise deployment activity. The division secured new multi-year contracts with Bank Simpanan Nasional, Bank BTPN, FE Credit, E.ON and AXA and continued to see high renewal rates.
■
Identity: revenue grew 11.5% y-o-y on a reported basis and 8.5% on a constant currency organic basis. Adjusting for the one-off benefit from the stimulus programme in FY21, underlying revenue grew 17.1%. New customers include Hymans Robertson, St James’s Place, Nintendo and CUNA Mutual. Acuant (acquired 29 November 2021) contributed revenue of £12.3m and Cloudcheck (acquired 31 January) contributed £0.34m.
■
Location: revenue grew 11.2% y-o-y on a reported basis and 12.7% on a constant currency organic basis, benefiting from the ongoing consumer shift to online activity. New customers include ASICS, HarperCollins, Spotify and JetBlue Airways.
Exhibit 2: Divisional revenue and operating profit (£m)
FY22a |
FY22e |
FY21a |
diff |
y-o-y |
Constant currency (cc) organic growth |
|
Revenues |
||||||
Fraud |
33.3 |
32.9 |
28.4 |
1.3% |
17.1% |
15.7% |
Identity |
142.8 |
138.7 |
128.1 |
3.0% |
11.5% |
8.5% |
Location |
66.3 |
70.4 |
59.7 |
-5.8% |
11.2% |
12.7% |
Unallocated |
0.0 |
0.0 |
1.5 |
0.0% |
(97%) |
N/A |
Total revenues |
242.5 |
242.0 |
217.7 |
0.2% |
11.4% |
10.6% |
Adjusted operating profit |
||||||
Fraud |
8.0 |
9.9 |
5.3 |
-18.7% |
50.5% |
|
Identity |
57.0 |
54.9 |
47.7 |
4.0% |
19.4% |
|
Location |
24.6 |
24.7 |
19.5 |
-0.5% |
26.3% |
|
Unallocated |
-30.8 |
-31.5 |
-14.7 |
-2.1% |
N/A |
|
Total adjusted operating profit |
58.8 |
58.0 |
57.9 |
1.5% |
1.6% |
|
Adjusted operating margin |
||||||
Fraud |
24.1% |
30.0% |
18.7% |
-5.9% |
5.3% |
|
Identity |
39.9% |
39.6% |
37.3% |
0.4% |
2.7% |
|
Location |
37.1% |
35.1% |
32.6% |
2.0% |
4.5% |
|
Unallocated |
N/A |
N/A |
N/A |
N/A |
N/A |
|
Total adjusted operating margin |
24.3% |
24.0% |
26.6% |
0.3% |
-2.3% |
Source: GB Group, Edison Investment Research
Exhibit 3 below shows the split of revenue by contract type. To clarify, a consumption-based subscription licence is one where the customer pays in advance for a set number of transactions over a period of time. If the customer does not use all the transactions paid for in the period, they are forfeited. Conversely, a consumption contract is one where the customer pays in arrears based on the number of transactions undertaken in a period. More than three-quarters of the Identity business is contracted on a consumption basis, that is, customers pay per verification. Conversely, nearly three-quarters of Fraud revenue is contracted on a subscription licence basis, with most licences for a multi-year term and only a small proportion on a consumption basis. The Location business has more than 90% of revenue from subscription licences, with more than two-thirds of these on a term basis. At a group level, this results in 49% of revenue generated from subscription licences (33% consumption based, 67% term based), 44% from consumption-based contracts and 7% from other (mainly services).
Exhibit 3: Group revenues by type (£000s)
FY21 |
FY22 |
% of revenue FY21 |
% of revenue FY22 |
Growth y-o-y |
|
Consumption based |
32,750 |
35,830 |
14 |
16 |
9% |
Term based |
62,244 |
76,465 |
30 |
33 |
23% |
Subscription revenues |
94,994 |
112,295 |
44 |
49 |
18% |
Consumption |
111,265 |
115,212 |
52 |
44 |
4% |
Other |
11,400 |
14,973 |
4 |
7 |
31% |
Total revenue |
217,659 |
242,480 |
100 |
100 |
11% |
Source: GB Group
Integration of Acuant well underway
During Q422, the company combined the Acuant and IDology teams to create the largest pure-play identity verification and fraud prevention provider in the Americas. GBG has already implemented £3m of the planned £5m FY23 synergy target, mainly via cost synergies, and has a strong pipeline of cross-selling opportunities that should help it achieve revenue synergies to make up the remaining £2m.
Acuant and IDology had been selling each other’s products over the last few years. The go-to-market teams have now been combined and the single US entity now provides IDology with more cost-effective document verification and Acuant with better access to IDology products to sell within its Compliance platform.
Product launches across the business
During the year, GBG has released several enhanced identity services: Expect ID Flex API for US enterprise customers, ProID for SMEs in EMEA and a low-code/no-code version of the Green ID platform in APAC. The Location business released the latest generation of its advanced address capture solution. The Fraud business integrated the Investigate solution into its platform, having gained the capability in late 2020 through the Hooyu acquisition.
Creating a global products group
During H222, the company formed its global products group, demonstrating just one of the ways that GBG is bringing together Acuant and GBG’s identity verification and fraud prevention roadmaps. The plan is to accelerate the data, product and platform strategy by around two years, focusing on developing a consistent global experience for customers. GBG plans to offer the market’s largest, continuously updated identity document library, and is targeting the release of its cloud-based fraud prevention solution in H223.
Outlook and changes to forecasts
GBG benefited in Q122 from high volumes of cryptocurrency transactions and the continuation of the US COVID-19 stimulus project; this creates a tough comparative for H123. However, management believes it is well positioned to achieve its strategic and financial objectives for FY23 and is confident in its ability to deliver the targeted synergies from the Acuant acquisition.
We have made minimal changes to our revenue and adjusted operating profit forecasts for FY23/24 and we introduce forecasts for FY25. We have increased our dividend forecast by 11% in FY23 and 16% in FY24. We factor in higher working capital requirements, which increases our net debt forecast at the end of FY23 from £58m to £69m.
Exhibit 4: Changes to forecasts
£m |
FY23e |
FY23e |
|
|
FY24e |
FY24e |
|
|
FY25e |
|
|
old |
new |
Change |
y-o-y |
old |
new |
change |
y-o-y |
new |
y-o-y |
||
Revenues |
300.5 |
300.8 |
0.1% |
24.0% |
336.7 |
337.0 |
0.1% |
12.1% |
379.5 |
12.6% |
|
Gross profit |
216.4 |
213.5 |
(1.3%) |
24.2% |
242.5 |
239.3 |
(1.3%) |
12.1% |
269.5 |
12.6% |
|
Gross margin |
72.0% |
71.0% |
(1.0%) |
0.1% |
72.0% |
71.0% |
(1.0%) |
0.0% |
71.0% |
0.0% |
|
EBITDA |
76.0 |
75.8 |
(0.3%) |
21.8% |
84.8 |
85.5 |
0.8% |
12.8% |
96.2 |
12.6% |
|
EBITDA margin |
25.3% |
25.2% |
(0.1%) |
(0.5%) |
25.2% |
25.4% |
0.2% |
0.2% |
25.3% |
(0.0%) |
|
EBITA |
72.1 |
72.2 |
0.1% |
22.7% |
80.7 |
81.7 |
1.2% |
13.2% |
92.3 |
12.9% |
|
EBITA margin |
24.0% |
24.0% |
0.0% |
(0.3%) |
24.0% |
24.3% |
0.3% |
0.2% |
24.3% |
0.1% |
|
PBT |
68.9 |
67.7 |
(1.8%) |
18.6% |
78.1 |
78.0 |
(0.0%) |
15.3% |
89.4 |
14.6% |
|
EPS - normalised, diluted (p) |
20.5 |
20.4 |
(0.5%) |
1.0% |
22.8 |
22.8 |
(0.0%) |
11.6% |
25.9 |
13.9% |
|
EPS - reported (p) |
13.7 |
11.0 |
(19.6%) |
56.1% |
16.3 |
13.9 |
(14.6%) |
26.0% |
17.0 |
22.4% |
|
DPS (p) |
3.6 |
4.0 |
11.1% |
5.0% |
3.7 |
4.3 |
16.2% |
7.5% |
4.6 |
7.0% |
|
Net debt/(cash) |
58.2 |
68.5 |
17.8% |
(35.3%) |
6.1 |
19.3 |
216.4% |
(71.9%) |
(38.6) |
(300.4%) |
|
Net debt/EBITDA (x) |
0.8 |
0.9 |
0.1 |
0.2 |
N/A |
||||||
Source: Edison Investment Research
Valuation
The share price is down c 40% year-to-date and is trading on a P/E of 21.6x FY23e and 19.4x FY24e. This is the lowest level it has traded at since autumn 2019, bar the dip in March 2020. The company flagged the tough comparison period for H123 and indicated that despite this, it was happy with FY23 forecasts. As the company trades through H123 and gains a better idea of underlying growth and the scale of revenue synergies from the Acuant deal, it should be able to provide the market with confidence that FY23 estimates are achievable and that the acquisition of Acuant is delivering on its promise.
Our reverse DCF (8% WACC raised to reflect rising interest rates, 3% perpetuity growth after 10 years, explicit forecasts to FY25), implies the share price is discounting organic revenue growth of approximately 3% from FY26–FY32, assuming a stable EBIT margin (in line with management’s policy). This growth rate is significantly lower than the double-digit rate GBG has targeted for some time and, considering that Acuant is expected to grow faster than the original GBG business, this appears low. Increasing the revenue growth rate to 12% from FY26, the bottom of management’s 12–14% range, would increase the value to 749p per share.
Exhibit 5: Financial summary
£'000s |
2020 |
2021 |
2022 |
2023e |
2024e |
2025e |
||
March |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
||
PROFIT & LOSS |
||||||||
Revenue |
|
|
199,101 |
217,659 |
242,480 |
300,767 |
337,045 |
379,510 |
Cost of Sales |
(54,914) |
(65,096) |
(70,549) |
(87,222) |
(97,743) |
(110,058) |
||
Gross Profit |
144,187 |
152,563 |
171,931 |
213,544 |
239,302 |
269,452 |
||
EBITDA |
|
|
51,739 |
61,410 |
62,196 |
75,766 |
85,474 |
96,204 |
Operating Profit (before amort. and except.) |
|
47,945 |
57,896 |
58,839 |
72,204 |
81,747 |
92,303 |
|
Acquired intangible amortisation |
(19,008) |
(17,671) |
(24,735) |
(24,735) |
(24,735) |
(24,735) |
||
Exceptionals |
(1,552) |
448 |
(4,526) |
0 |
0 |
0 |
||
Share of associate |
0 |
0 |
0 |
0 |
0 |
0 |
||
Share based payments |
(4,541) |
(5,170) |
(6,171) |
(6,788) |
(7,467) |
(8,214) |
||
Operating Profit |
22,844 |
35,503 |
23,407 |
40,681 |
49,545 |
59,355 |
||
Net Interest |
(2,218) |
(1,240) |
(1,754) |
(4,515) |
(3,705) |
(2,895) |
||
Profit Before Tax (norm) |
|
|
45,727 |
56,656 |
57,085 |
67,689 |
78,042 |
89,408 |
Profit Before Tax (FRS 3) |
|
|
20,626 |
34,263 |
21,653 |
36,166 |
45,840 |
56,460 |
Tax |
(3,562) |
(7,385) |
(6,390) |
(8,318) |
(10,543) |
(12,986) |
||
Profit After Tax (norm) |
35,210 |
44,481 |
44,498 |
52,121 |
58,531 |
67,056 |
||
Profit After Tax (FRS 3) |
17,064 |
26,878 |
15,263 |
27,848 |
35,297 |
43,474 |
||
Ave. Number of Shares Outstanding (m) |
193.6 |
195.2 |
216.2 |
252.6 |
254.1 |
255.6 |
||
EPS - normalised (p) |
|
|
18.2 |
22.8 |
20.6 |
20.6 |
23.0 |
26.2 |
EPS - normalised and fully diluted (p) |
|
|
17.9 |
22.4 |
20.2 |
20.4 |
22.8 |
25.9 |
EPS - (IFRS) (p) |
|
|
8.8 |
13.8 |
7.1 |
11.0 |
13.9 |
17.0 |
Dividend per share (p) |
0.0 |
6.4 |
3.8 |
4.0 |
4.3 |
4.6 |
||
Gross Margin (%) |
72.4 |
70.1 |
70.9 |
71.0 |
71.0 |
71.0 |
||
EBITDA Margin (%) |
26.0 |
28.2 |
25.6 |
25.2 |
25.4 |
25.3 |
||
Operating Margin (before GW and except.) (%) |
24.1 |
26.6 |
24.3 |
24.0 |
24.3 |
24.3 |
||
BALANCE SHEET |
||||||||
Fixed Assets |
|
|
430,219 |
394,564 |
1,001,090 |
978,261 |
955,520 |
942,863 |
Intangible Assets |
414,505 |
377,663 |
969,561 |
944,876 |
920,241 |
895,656 |
||
Tangible Assets |
9,420 |
6,937 |
7,343 |
9,199 |
11,093 |
13,021 |
||
Other fixed assets |
6,294 |
9,964 |
24,186 |
24,186 |
24,186 |
34,186 |
||
Current Assets |
|
|
95,984 |
85,653 |
101,017 |
129,921 |
161,070 |
202,702 |
Debtors |
66,554 |
58,617 |
69,715 |
90,230 |
101,113 |
113,853 |
||
Cash |
27,499 |
21,135 |
22,302 |
29,691 |
48,957 |
76,848 |
||
Other |
1,931 |
5,901 |
9,000 |
10,000 |
11,000 |
12,000 |
||
Current Liabilities |
|
|
(86,459) |
(90,000) |
(115,795) |
(134,080) |
(148,827) |
(166,440) |
Creditors |
(80,280) |
(86,338) |
(109,939) |
(128,224) |
(142,971) |
(160,584) |
||
Contingent consideration |
(6,179) |
(3,662) |
(5,856) |
(5,856) |
(5,856) |
(5,856) |
||
Short term borrowings |
0 |
0 |
0 |
0 |
0 |
0 |
||
Long Term Liabilities |
|
|
(94,810) |
(25,961) |
(199,185) |
(161,935) |
(122,967) |
(93,601) |
Long term borrowings |
(62,139) |
0 |
(128,226) |
(98,226) |
(68,226) |
(38,226) |
||
Contingent consideration |
0 |
0 |
(1,920) |
(1,920) |
(1,920) |
(1,920) |
||
Other long term liabilities |
(32,671) |
(25,961) |
(69,039) |
(61,789) |
(52,821) |
(53,455) |
||
Net Assets |
|
|
344,934 |
364,256 |
787,127 |
812,167 |
844,796 |
885,524 |
CASH FLOW |
||||||||
Operating Cash Flow |
|
|
48,498 |
72,631 |
56,256 |
72,536 |
88,337 |
100,078 |
Net Interest |
(1,768) |
(1,211) |
(1,373) |
(4,515) |
(3,705) |
(2,895) |
||
Tax |
(6,386) |
(14,205) |
(11,610) |
(15,569) |
(19,510) |
(22,352) |
||
Capex |
(1,339) |
(738) |
(1,731) |
(3,400) |
(3,550) |
(3,700) |
||
Acquisitions/disposals |
(81) |
2,545 |
(460,484) |
0 |
0 |
0 |
||
Financing |
(1,553) |
3,476 |
298,219 |
(2,067) |
(2,171) |
(2,279) |
||
Dividends |
(5,761) |
(5,883) |
(6,677) |
(9,596) |
(10,135) |
(10,959) |
||
Net Cash Flow |
31,610 |
56,615 |
(127,400) |
37,389 |
49,266 |
57,892 |
||
Opening net debt/(cash) |
|
|
65,699 |
34,640 |
(21,135) |
105,924 |
68,535 |
19,269 |
HP finance leases initiated |
0 |
0 |
0 |
0 |
0 |
0 |
||
Other |
(551) |
(840) |
341 |
0 |
0 |
0 |
||
Closing net debt/(cash) |
|
|
34,640 |
(21,135) |
105,924 |
68,535 |
19,269 |
(38,622) |
Source: GB Group, Edison Investment Research
|
|
Research: Healthcare
Sales of Basilea’s antifungal drug, Cresemba (isavuconazole), in the Asia Pacific region have triggered a milestone payment of $1.25m from the company’s licence partner Pfizer, management has reported. Global Cresemba sales were $324m in FY21, resulting in significant royalty and milestone payments to Basilea. In our view, the triggering of milestones in new regions (Asia Pacific) is encouraging for Cresemba’s future sales growth. Cresemba is approved in 68 countries and marketed in 57 and is a key revenue driver for Basilea. Considerable past milestone payments from partners (Pfizer, Astellas) provide support that management is addressing a worldwide unmet medical need with Cresemba. We value Basilea Pharmaceutica at CHF847.7m or CHF71.6/share.